Doctor Thierry Facon, professor of Haematology at Lille University Hospital in France explains the results of the Phase 3 IMROZ study, comparing isatuximab, bortezomib, lenalidomide and dexamethasone, known as Isa-VRd, ...versus VRd for transplant-ineligible patients with newly diagnosed myeloma at the European Hematology Association annual congress in Madrid, Spain.[+] Show More
Doctor Thierry Facon, professor of Haematology at Lille University ...
Doctor Dimopoulos explains the DREAMM-8 study, one of the ...
Doctor Dimopoulos explains the DREAMM-7 study presented at the 2024 ...
Professor Doctor Uyl-de Groot explains fair pricing in haematology ...
Maria Cavaller Bellaubi, Patient Engagement and Development Director, ...
Doctor Kumar explains the CAMMA 2 study presented at the 2024 European ...
In this video, Dr. Krzysztof Giannopoulos, Department of Experimental ...
In this video, Carmen Gonzalez, Cancer Center Clinica Universidad de ...
In this video, Prof. Pieter Sonneveld, Head of the Department of ...
In this video, Dr.Sæmundur Rögnvaldsson, Faculty of Medicine, ...
In this video, Dr. Moshe Gatt, Department of Haematology, Hebrew ...
In this video, the chair of the ESMO Patient Advocates Working Group ...
1
of 8